[go: up one dir, main page]

LU86383A1 - Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique - Google Patents

Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique Download PDF

Info

Publication number
LU86383A1
LU86383A1 LU86383A LU86383A LU86383A1 LU 86383 A1 LU86383 A1 LU 86383A1 LU 86383 A LU86383 A LU 86383A LU 86383 A LU86383 A LU 86383A LU 86383 A1 LU86383 A1 LU 86383A1
Authority
LU
Luxembourg
Prior art keywords
sodium
solution
phenytotne
phenytoin
chollne
Prior art date
Application number
LU86383A
Other languages
English (en)
French (fr)
Inventor
Mahdi B Fawzi
Anne K Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of LU86383A1 publication Critical patent/LU86383A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU86383A 1985-05-20 1986-04-01 Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique LU86383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/735,932 US4642316A (en) 1985-05-20 1985-05-20 Parenteral phenytoin preparations
US73593285 1985-05-20

Publications (1)

Publication Number Publication Date
LU86383A1 true LU86383A1 (fr) 1986-09-02

Family

ID=24957819

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86383A LU86383A1 (fr) 1985-05-20 1986-04-01 Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique

Country Status (18)

Country Link
US (1) US4642316A (it)
JP (1) JPS61268618A (it)
AU (1) AU595790B2 (it)
BE (1) BE904476A (it)
CA (1) CA1268119A (it)
CH (1) CH668594A5 (it)
DE (1) DE3610330A1 (it)
DK (1) DK100786A (it)
ES (1) ES8707195A1 (it)
FR (1) FR2581871B1 (it)
GB (1) GB2175203B (it)
IT (1) IT1190282B (it)
LU (1) LU86383A1 (it)
NL (1) NL8600899A (it)
NZ (1) NZ215783A (it)
PH (1) PH22922A (it)
SE (1) SE8600998L (it)
ZA (1) ZA862094B (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828156A1 (de) * 1988-08-19 1990-02-22 Astrapin Pharmazeutische Praep Stabile waessrige loesung von fluorouracil
WO1999004798A1 (en) * 1997-07-22 1999-02-04 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
WO1999048876A1 (en) 1998-03-20 1999-09-30 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
AU2003288588A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited An extended release pharmaceutical composition of phenytoin sodium
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
DE102005019393A1 (de) * 2005-04-25 2006-10-26 Basell Polyolefine Gmbh Polyethylenformmassen für Spritzgussanwendungen
ES2380887T3 (es) 2005-05-13 2012-05-21 Topotarget Uk Limited Formulaciones farmacéuticas de inhibidores de la HDAC
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
EP1957056A2 (en) * 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
US8377979B2 (en) * 2005-12-05 2013-02-19 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
CA2700173C (en) * 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
PL2262493T3 (pl) * 2008-03-07 2015-08-31 Onxeo Dk Branch Of Onxeo S A France Sposoby leczenia wykorzystujące wydłużony ciągły wlew belinostatu
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
EP3777839A1 (en) 2009-05-19 2021-02-17 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
SI2640358T1 (en) 2010-11-15 2018-05-31 Neuroderm Ltd. Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof
US9540330B2 (en) 2010-12-15 2017-01-10 Nektar Therapeutics Oligomer-containing hydantoin compounds
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
CN106413754B (zh) 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
WO2023205615A1 (en) * 2022-04-18 2023-10-26 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions & methods of their use
US12109303B2 (en) 2022-04-18 2024-10-08 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions and methods of their use
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
JPS5221575B2 (it) * 1972-03-18 1977-06-11
US4163058A (en) * 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins

Also Published As

Publication number Publication date
DK100786D0 (da) 1986-03-05
FR2581871B1 (fr) 1990-05-11
DK100786A (da) 1986-11-21
SE8600998D0 (sv) 1986-03-05
SE8600998L (sv) 1986-11-21
ZA862094B (en) 1986-11-26
CA1268119A (en) 1990-04-24
NL8600899A (nl) 1986-12-16
US4642316A (en) 1987-02-10
DE3610330A1 (de) 1986-11-20
NZ215783A (en) 1989-01-27
GB2175203B (en) 1988-09-14
GB8607383D0 (en) 1986-04-30
ES8707195A1 (es) 1987-07-16
AU5441286A (en) 1986-11-27
JPS61268618A (ja) 1986-11-28
BE904476A (fr) 1986-09-24
GB2175203A (en) 1986-11-26
IT1190282B (it) 1988-02-16
IT8647936A0 (it) 1986-04-24
AU595790B2 (en) 1990-04-12
CH668594A5 (fr) 1989-01-13
ES555143A0 (es) 1987-07-16
PH22922A (en) 1989-01-24
FR2581871A1 (fr) 1986-11-21

Similar Documents

Publication Publication Date Title
LU86383A1 (fr) Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique
CA2102778C (fr) Nouvelles compositions a base de derives de la classe des taxanes
EP0078785B1 (fr) Sels d'acide valproîque, leur préparation et leur utilisation
CN1079668C (zh) 注射用脂质体药物制剂
FR2466248A1 (fr) Derives d'agents anti-inflammatoires non steroides, procede de preparation et compositions pharmaceutiques les contenant
CN101621997B (zh) 医药组合物
EP0835140B1 (fr) Complexes metalliques de polyaminoacides et leur utilisation en imagerie diagnostique
KR101443826B1 (ko) 의약조성물
FR2584405A1 (fr) Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation
CA1281650C (en) Aqueous preparation containing cyclodextrin
EP0099799B1 (fr) Nouveaux sels d'amino- (et imino-) acides alpha, omega-sulfoniques N-substitués, vecteurs cationiques de haute pénétration cellulaire, procédé d'obtention
JP3917820B2 (ja) オザグレルナトリウム含有注射液およびその安定化方法
EP0092287B1 (fr) Sels d'acétylcystéine, leur préparation et leur utilisation
RU2313346C2 (ru) Фармацевтическая композиция
FR2690340A1 (fr) Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
FR2535205A1 (fr) Solution pour injection a base de substances antirhumatismales et d'une cobalamine et procede pour sa preparation
JP2007106736A (ja) 注射用の医薬組成物
JP2007191417A (ja) 医薬用の組成物
Cavallito et al. Complexation of ammonium salts with phenols
JP2003063963A (ja) オザグレルナトリウム含有注射液
LU83081A1 (fr) Compositions antitumeurs
BE887220A (fr) Compositions antitumeurs
JP2007077060A (ja) 注射用の医薬組成物
FR2803515A1 (fr) Solution aqueuse stable de deoxyfructosazine
JP2007091674A (ja) 注射用の医薬組成物